GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Dec 31, 2021

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-22-000004General Corporate
Debt relative to revenue35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

132.96% · OPTIONAL · VALID

Capex intensity5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.18% · OPTIONAL · VALID

Operating cash generation20thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

1.54% · OPTIONAL · VALID

Revenue growth40thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

3.67% · CORE · VALID

Inventory pressure25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

37.80% · OPTIONAL · VALID

Operating margin10thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-18.41% · CORE · VALID

R&D intensity30thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

5.26% · OPTIONAL · VALID

SBC intensity75thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.85% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
387.99%
Current
132.96%
Delta
-255.03%
Capex Intensity Increased
Previous
1.10%
Current
1.18%
Delta
0.09%
Cash Generation Increased
Previous
-10.38%
Current
1.54%
Delta
11.91%
Growth Increased
Previous
-1.73%
Current
3.67%
Delta
5.41%
Inventory Pressure Decreased
Previous
118.48%
Current
37.80%
Delta
-80.69%
Profitability Decreased
Previous
-6.84%
Current
-18.41%
Delta
-11.57%
R And D Intensity Increased
Previous
4.72%
Current
5.26%
Delta
0.54%
Sbc Intensity Decreased
Previous
5.39%
Current
4.85%
Delta
-0.54%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.